Erasca Inc
ERASHealthcare|Biotechnology|USA
$18.53
-0.65 (-3.39%)
Tangible Book
$1.27
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06346067 A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | Advanced or Metastatic NRAS-mutant Melanoma | P3 | Active | 78 | RCT, Open-label | Naporafenib, Dacarbazine, Temozolomide, Trametinib |
| NCT04866134 A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | P1P2 | Active | 200 | Open-label | ERAS-007, ERAS-601 |
| NCT05222802 A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | Glioblastoma Multiforme | P1 | Active | 52 | Open-label | ERAS-801 |
| NCT06983743 A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | Metastatic Solid Tumors | P1 | Recruiting | 600 | Open-label | ERAS-0015, ERAS-0015 in combination |
| NCT07021898 A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. | Metastatic Solid Tumors | P1 | Recruiting | 200 | Open-label | ERAS-4001, ERAS-4001 in combination |
| NCT04670679 A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | P1 | Active | 90 | Open-label | ERAS-601, Cetuximab, Pembrolizumab |
| NCT05907304 A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations | Advanced or Metastatic Solid Tumors | P1 | Active | 86 | Open-label | Naporafenib, Trametinib |
| NCT05039177 A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies | Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | P1P2 | Completed | 101 | Open-label | ERAS-007, Encorafenib, Cetuximab, Palbociclib |
| NCT05279859 A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | Acute Myeloid Leukemia | P1P2 | Withdrawn | — | Open-label | ERAS-007, ERAS-601, Gilteritinib |
| NCT04959981 A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | Advanced Non-squamous Non-small-cell Lung Cancer | P1 | Completed | 24 | Open-label | ERAS-007, ERAS-601, Osimertinib, Sotorasib |